BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33063618)

  • 21. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
    Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
    [No Abstract]   [Full Text] [Related]  

  • 22. ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases.
    Song Z; Zheng Y; Wang X; Su H; Zhang Y; Song Y
    J Thorac Dis; 2017 Oct; 9(10):3919-3926. PubMed ID: 29268402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma.
    Xu Y; Chang H; Wu L; Zhang X; Zhang L; Zhang J; Li Y; Shen L; Zhu X; Zhou X; Bai Q
    Exp Mol Pathol; 2020 Dec; 117():104548. PubMed ID: 32979347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
    Xu L; Lei J; Wang QZ; Li J; Wu L
    Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Genetic Profile of Young Chinese Patients with Lung Adenocarcinoma].
    Liang Y; Hou H; Jiang M; Zhang C; Liu D; Zhang X
    Zhongguo Fei Ai Za Zhi; 2020 Apr; 23(4):239-246. PubMed ID: 32316711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
    Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
    Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
    [No Abstract]   [Full Text] [Related]  

  • 28. [Relationship between EGFR, ALK Gene Mutation and Imaging 
and Pathological Features in Invasive Lung Adenocarcinoma].
    Yang H; Liu Z; Wang H; Chen L; Wang J; Wen W; Xu X; Zhu Q
    Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):147-155. PubMed ID: 35340157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion.
    Wu SG; Liu YN; Yu CJ; Yang JC; Shih JY
    Genes Chromosomes Cancer; 2018 Oct; 57(10):513-521. PubMed ID: 30107055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
    Gow CH; Hsieh MS; Wu SG; Shih JY
    Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma.
    Wang Q; Lv Y; Zhong M; Zhu F; Wei L; Shi H
    J BUON; 2017; 22(4):1053-1060. PubMed ID: 28952227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ALK, ROS1 and EGFR status of lung cancers in the Aegean Region of Turkey.
    Diniz G; Komurcuoglu B; Ozyilmaz B; Ozguzer A; Yucel N; Kirbiyik O
    Indian J Pathol Microbiol; 2022; 65(2):305-310. PubMed ID: 35435363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
    Zhang S; Yan B; Zheng J; Zhao J; Zhou J
    Oncotarget; 2016 Sep; 7(39):63758-63766. PubMed ID: 27563816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
    Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
    Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
    Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.
    Kuang X; Xiao J; Dai LX; Zhang LH; He BX
    Transl Cancer Res; 2019 Jun; 8(3):736-751. PubMed ID: 35116812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma.
    Liu X; Jiang G; Sun X; Su G; Zhang X; Shen D; Yan N
    Front Oncol; 2023; 13():1275575. PubMed ID: 38023198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
    Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
    Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor and anaplastic lymphoma kinase mutation in adenocarcinoma lung: Their incidence and correlation with histologic patterns.
    Gupta P; Gowrishankar S; Swain M
    Indian J Pathol Microbiol; 2019; 62(1):24-30. PubMed ID: 30706855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.